行情

EDIT

EDIT

Editas Medicine
NASDAQ

实时行情|Nasdaq Last Sale

30.64
-1.38
-4.31%
盘后: 30.85 +0.21 +0.69% 18:20 01/17 EST
开盘
32.20
昨收
32.02
最高
32.20
最低
30.42
成交量
100.81万
成交额
--
52周最高
34.37
52周最低
19.00
市值
15.65亿
市盈率(TTM)
-12.4028
分时
5日
1月
3月
1年
5年

分析师评级

9位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

EDIT 新闻

  • These Gene-Editing Pioneers Are Making Bold Bets in Agriculture
  • MotleyFool.com.1天前
  • European ruling threatens Broad's CRISPR gene-editing patents
  • American City Business Journals.2天前
  • The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics
  • Benzinga.3天前
  • The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance
  • Benzinga.4天前

更多

所属板块

生物技术和医学研究
-0.16%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

EDIT 简况

Editas Medicine, Inc. is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. Its platform consists of four components: nuclease engineering, delivery, control and specificity, and directed editing. Its programs include Eye Diseases, Engineered T Cell Therapies for Immuno-Oncology and additional research programs. It is developing a genome editing therapeutic for Leber Congenital Amaurosis type 10 (LCA10).
展开

Webull提供Editas Medicine Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。